Permanent discontinuation of study
medication was required by protocol for women who developed breast cancer, endometrial pathologic state (hyperplasia not responsive to treatment, atypia, or cancer),
deep vein thrombosis (DVT) or PE, malignant melanoma, meningioma, triglyceride level greater
than 1000 mg / dL (11.3 mmol / L), or prescription of estrogen, testosterone, or selective estrogen - receptor modulators by their personal physician.